
may pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
see sale rise
follow declin aid
hospira mediv acquisit
advers impact divestitur
brand product ibranc
xeljanz eliqui partner
bristol-my see flat sale prevnar
 adult
alreadi vaccin see growth
pediatr sale global
mdvn billion see sale mdvn
prostat cancer drug xtandi co-promot
astella pharma grow solidli next
premium mdvn oncolog product
includ pipelin compound talazoparib
breast cancer pidilizumab lymphoma
billion
see ep
activ buy back share
repurchas share decemb
board author new share
repurchas program januari
author billion
think share trade
ep estim gener drug
peer brand drug peer near fair
valu think share trade
discount brand peer
gener unit account sale
grow slowli lower margin
expect essenti health sale improv
anticip grow biosimilar sale
continu pursu acquisit
supplement growth think
significantli overpaid recent acquisit
februari sold hospira infus
unit billion
announc spin
reiter decis regard consum
healthcar unit includ spin-off sale
transact made
think sale could potenti bring
risk recommend target price
includ potenti pipelin setback
target price base
ep estim brand
peer gener peer
risk assess reflect promin posit
global pharmaceut market afford
import competit oper financi
advantag howev compani still subject
inher risk common pharmaceut compani
relat discoveri develop
regulatori clearanc success commerci
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview growth sinc larg augment major acquisit --
warner-lambert pharmacia -- well in-licens product busi
significantli expand acquisit wyeth octob recent acquisit
includ hospira septemb billion mediv septemb billion
drug portfolio unmatch term breadth depth global drug market view
compani largest sell drug lyrica treatment nerv pain epilept seizur
prevnar/prevnar vaccin key drug includ ibranc treat breast cancer enbrel
treatment moder sever plaqu psoriasi rheumatoid arthriti sold outsid
 canada lipitor cholesterol-low agent largest-sel drug mani year
sale fell sharpli follow expir market exclus novemb
key drug sold includ viagra male erectil dysfunct norvasc antihypertens agent
sutent kidney cancer premarin femal hormon replac treatment benefix
recombin coagul therapi certain type hemophilia larg number drug
gener sale hundr million encompass treatment wide rang diseas
medic condit consum health care product includ over-the-counter medicin dietari supplement
item zoeti anim health unit spun sharehold
primari busi dynam adjust spend total billion billion
sale sale spend downtrend recent year
part on-going cost reduct program rose octob
pipelin consist compound total late-stag phase
registr compound includ new treatment wide rang condit includ cancer aid
obes arthriti heart diseas diabet schizophrenia pain
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate period accord forecast made im
key driver emerg market whose aggreg sale countri project
advanc compound-annual-growth-rate period growth develop market spur
rise standard live grow govern spend health care howev im forecast
declin trend europ impact auster price combin drug spend five major
european market project declin compound-annual-growth-rate convers spend
 forecast grow compound-annual-growth-rate period
impact major develop mid-octob acquir rival drugmak wyeth
billion cash stock financ transact billion cash billion
debt billion common stock think acquisit significantli expand
exposur biolog vaccin new pharmaceut market view realiz
estim billion annual synergi wyeth integr februari acquir king
pharmaceut billion cash king brought pfizer grow portfolio novel pain
treatment well larg anim health product busi june acquir anacor
pharmaceut billion septemb acquir mediv mdvn billion
financi trend early-februari made ipo offer million class share
interest zoeti new firm compris anim health divis late june
subsequ exchang remain million share interest million
share retir forma sale fallen billion billion
repres compound annual growth rate howev aid acquisit sale rose
billion oper ep declin repres
compound annual growth rate aid significantli cost cut stock repurchas
oper ep rose
execut vice-president busi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook pharmaceut
sub-industri next month neutral
although believ trump
administr push regulatori
chang forc drug price believ
third parti payer health insur
pharmaci benefit manag pbm along
public pressur media effect
pharmaceut firm announc
rais price drug
year histor drug price increas
account signific portion firm
tweet work new
system competit
drug industri drug price
come follow comment share
price drug firm declin markedli
volatil industri increas
price innov work group
releas draft execut order aim
tackl high drug price draft focus
reduc regul method increas
competit lower drug price strengthen
properti right scale back discount
given hospit serv lower incom
patient import note mani
individu serv work group
former pharmaceut execut like
cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
howev see modest benefit
foreign exchang follow
soften dollar late
also see expand sale new innov
drug therapi margin improv
accru cost restructur merger
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
april
declin composit index
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
increas competit ibranc recent approv drug essenti health
sale fell biosimilar sale driven inflectra rose see similar
trend brand gener sale throughout /jeffrey loo cfa
et capit iq keep hold opinion share
inc lower target in-lin
peer revis ep estim set
ep estim ep vs
estim sale declin slightli wider forecast
guid sale exclus pend hospira infus system sale
ep note sale growth
come acquisit see continu challeng organ growth
howev expect robust ibranc sale
analyst research note compani news
keep target ep estim
brand peer gener peer ep vs
ahead view partli lower tax rate vs year ago
howev sale growth sale growth forecast due
softer-than-expect sale arthriti drug xeljanz breast cancer drug
ibranc biosimilar competit europ enbrel along continu soft
sale essenti health unit lower gener price sale prevnar
fell sale intern sale say
compound develop could reach commerci
potenti achiev annual sale separ state
receiv fair valu sale consum health care
busi like retain invest unit howev also left
open potenti spin-off pursu joint ventur unit
rais target peer
ep estim set ep vs
ahead estim sale exclud divestitur
hospira infus system rose innov health sale rose strong
eliqui xeljanz sale essenti health sale fell gener
price pressur guid sale ep
use tax rate reiter decis
regard consum healthcar made /jeffrey loo cfa
et cfra keep hold opinion share inc
keep target forward ep
estim ep vs ahead estim
rais ep estim
sale account divestitur hospira infus rose innov
sale rose essenti fell look essenti
sale improv anticip grow biosimilar sale strong
emerg market sale indic strateg decis regard
consum healthcar busi made /jeffrey loo cfa
said review strateg altern
consumer-health unit sell brand advil centrum
chapstick gener sale believ signific
interest numer buyer capabl pay believ
unit could fetch think would use proce pursu deal
brand pharma unit struggl slow growth lack
blockbust howev ceo ian read indic would prudent wait
see tax reform enact would impact valuat asset
keep target forward ep
brand peer gener peer ep vs
line view sale account sale hospira infus
system fell innov health rose essenti health fell
say receiv approv next year
potenti blockbust half blockbust
approv think project overli optimist see
keep target ep
estim brand peer gener peer ep
vs estim sale fell note less
sell day innov health sale rose solid ibranc sale
xtandi xeljanz sale expect howev see
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
